QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance

QuidelOrtho Corp

2025-Q2 EPS reported -$3.97 revenue$1,306,700,000

Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
GAAP net loss $255M ($3.77 loss per share) vs $148M loss prior year; includes $179M restructuring charges, notably $150M Savanna platform discontinuation.
Adjusted EBITDA $107M (17% margin, +330 bps YoY); achieved $100M annualized cost savings from 2024 initiatives.
Reiterates FY2025 guidance: revenue $2.60-$2.81B, adj. EBITDA $575-$615M, adj. diluted EPS $2.07-$2.57.
Announced intent to acquire LEX Diagnostics; initiated major manufacturing site consolidation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.